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and is substantial and therefore important in the context
of informal care. Almost half of the caregivers (48.2%)
derive positive utility from informal care and on average
happiness would decline if informal care tasks were
handed over to someone else. The multivariate analysis
shows that process utility is signiﬁcantly related to,
amongst other things, age and gender of the caregiver.
Male caregivers have lower process utility than female
caregivers. Closer relationship (partner, parent, child)
elicit lower process utility than others. CONCLUSIONS:
Process utility is impotant in the context of informal care.
Our results strengthen the idea of supporting informal
care, but also that of keeping a close eye on the position
of carers.
METHODOLOGICAL ISSUES—Utility Studies
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OBJECTIVES: This study aims to investigate if the results
of four published algorithms for calculating utility values
from assessments of SF-36 are in agreement with the
responses of traditional efﬁcacy variables assessed in a
randomized clinical study with different treatments of
asthmatic patients. METHODS: Data from a randomized
clinical study of moderate asthmatic patients comparing
treatment with budesonide alone (n = 114) with budes-
onide plus formoterol (n = 109) during 12 weeks are used
in this investigation. Utility values from the four algo-
rithms are calculated for the different treatment groups
at randomization and at end of treatment, and both
absolute values as well as change during treatment are
correlated with efﬁcacy variables assessed in the study:
PEF Morning, FEV1, and the summary score SF-36 PCS
from the SF-36 questionnaire. RESULTS: Mean Utility
values at baseline range between 0.61 to 0.82 for the 4
algorithms but with no difference between the two treat-
ment groups. Change during treatment varies between
0.08 and 0.11. While both PEF Morning and FEV1 are
statistically signiﬁcant when comparing the change during
treatment between the two treatment groups, neither any
of the SF-36 domains nor SF-36 PCS turns out to be. Two
out of the four utility measures, both based on TTO,
reaches statistical signiﬁcance. Correlation for change
during treatment shows moderate correlation with PEF
Morning (0.28 to 0.32) and FEV1 (0.17 to 0.25). CON-
CLUSION: The two utility measures based on the SF-36
items (or a subset thereof) and evaluated through TTO
show better response than the other two, one evaluated
through a Visual Analog Scale as rating scale, and the
other based on domain values and not item values from
SF-36.
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OBJECTIVE: The Centers for Medicare and Medicaid
Services (CMS) assigns a relative weight to those high 
cost new technology drugs designated with a non-
pass-through or expired pass-through payment status.
This study examines the conceptual approach of relative
weights for drugs and biologicals under the CMS Hospi-
tal Outpatient Prospective Payment System (OPPS) and
compares this approach to the resource-based level of
effort concept initially created for payment to physicians’
ofﬁces in the U.S. METHODS: The underlying intent of
relative value units (RVUs) in the physician’s ofﬁce was
to create a hierarchy of resource-based level of effort
involved in various types of ofﬁce-based service delivery.
The concept of hospital OPPS was also intended to reﬂect
resource-based services. Thus the OPPS relative weights
should be related to resource-based levels of effort. 
Non-pass-through high cost new technology drugs that
are paid separately under OPPS are assigned a relative
weight, implying that the payment includes level of effort
resources. We postulate these relative weights contain no
such level of effort, but instead represent only the pure
drug component. This use of the relative weight concept
distorts its initial intent. RESULTS: Resource-based
methods initially proposed for the hospital OPPS were
collected and deconstructed. CMS rationale supporting
treatment of non-pass-through high cost new technology
drugs paid separately under OPPS was identiﬁed. CMS
drug payment computation methods were likewise decon-
structed and evaluated. The evaluation sought indications
of resource-based level of effort applications. CONCLU-
SIONS: Many researchers and policy makers assume that
relative weights equate to level of effort resource con-
sumption in all instances. We cannot ﬁnd this is so in the
case of non-pass-through high cost new technology drugs
paid separately under OPPS. It is necessary to draw CMS
attention to this issue, as the volume of forthcoming new
drugs and biologics means the issue will become increas-
ingly important.
